AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citius Pharmaceuticals Reaches Nasdaq Compliance Milestone, Analysts Weigh In
ByAinvest
Thursday, Jul 10, 2025 3:44 pm ET1min read
Citius Pharmaceuticals regained Nasdaq compliance after maintaining a closing bid price of $1.00 or greater for 10 consecutive trading days. The company's stock is listed on the Nasdaq Stock Market, and Citius Pharma aims to deliver critical care products and create long-term value for shareholders. The latest analyst rating on CTXR stock is a Buy with a $100.00 price target.
Citius Pharmaceuticals, Inc. (CTXR) has successfully regained compliance with Nasdaq's minimum bid price requirement, a significant milestone for the biopharmaceutical company. The company's stock maintained a closing bid price of $1.00 or higher for 10 consecutive trading days, from June 20, 2025, to July 3, 2025 [2, 3]. This achievement has ensured that CTXR will continue to be listed and traded on the Nasdaq Stock Market, avoiding a potential delisting hearing [2, 3].Citius Pharmaceuticals, founded in 2007 and headquartered in Cranford, New Jersey, is dedicated to the development and commercialization of first-in-class critical care products. The company's FDA-approved product, LYMPHIR, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. Additionally, Citius Pharma's late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids [1].
The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023, with Mino-Lok meeting its primary and secondary endpoints [1]. Citius Pharmaceuticals is actively engaged with the FDA to determine the next steps for these programs.
The latest analyst rating on CTXR stock is a Buy with a $100.00 price target, reflecting investor confidence in the company's pipeline and strategic focus on critical care products [1].
References:
[1] https://finance.yahoo.com/quote/CTXR/
[2] https://www.gurufocus.com/news/2963406/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ctxr-stock-news
[3] https://www.prnewswire.com/news-releases/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302499666.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet